First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Overview of attention for article published in Lancet Oncology, October 2012
Altmetric Attention Score: 30
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
High Attention Score compared to outputs of the same age and source (80th percentile)
Mentioned by
- news
- 1 news outlet
- policy
- 1 policy source
- 8 X users
- patent
- 1 patent
- 1 Facebook page
- guideline
- 3 clinical guideline sources
Readers on
- mendeley
- 158 Mendeley